Medical marijuana a necessary prescription for opioid crisis
Twenty-nine states recognize the legal use of medical marijuana by statute, and an additional 16 states have approved access to compounds in the cannabis plant, such as cannabidiol, to treat specific conditions such as uncontrolled epilepsy.
Furthermore, the majority of the American public — including many leading health agencies like the American Nurses Association and the California Medical Association — enthusiastically support patients’ access to cannabis therapy. Given this reality, the question isn’t “Should marijuana be a medical option?” but rather “What motivates those who wish to deny Americans their right to this safe and effective therapy?”
One likely answer to this question: profit.
In recent years, players in Big Pharma and those associated with them have become prominent in their opposition to marijuana law reform. It’s easy to see why.
Marijuana is currently being recommended by doctors throughout the country to safely and effectively alleviate a wide range of symptoms, from chronic pain to anxiety to depression. This growing trend clearly cuts into the business models of companies such as Purdue Pharma, Pfizer and GlaxoSmithKlein — all of whom profit from the sales of opioid-based products and other conventional prescription drugs.